Topics

Newron Pharmaceuticals: Anpassung der Zahlen infolge H1-Ergebnisse

03:29 EDT 13 Sep 2019 | FinanzNachrichten

Zürich (www.aktiencheck.de) - Newron Pharmaceuticals-Aktienanalyse von Aktienanalyst Stefan Schneider von Vontobel Research: Stefan Schneider, Aktienanalyst von Vontobel Research, bestätigt in eine...

Original Article: Newron Pharmaceuticals: Anpassung der Zahlen infolge H1-Ergebnisse

NEXT ARTICLE

More From BioPortfolio on "Newron Pharmaceuticals: Anpassung der Zahlen infolge H1-Ergebnisse"

Quick Search

Relevant Topic

BioPortfolio - life science, medical devices and pharmaceutical conference
BioPortfolio is a leading news, information and knowledge resource covering the global life science industries impacted on by biotechnology. The site aims to provide the lay person, the researcher and the management executive with a single location to so...